Loading

Identification of Potential Inhibitor for Nucleoprotein of Lassa Virus: A Combination of Virtual Screening, ADMET Studies and Pharmacophore Modeling

Research Article | Open Access | Volume 2 | Issue 1

  • 1. Department of Biotechnology, Madhav Institute of Technology and Science, India
  • 2. Department of Biotechnology, Rama University, India
+ Show More - Show Less
Corresponding Authors
Sitansu Kumar Verma, Department of Biotechnology, Madhav Institute of Technology and Science, Gwalior, M.P - 474005, India Tel: 91-7047588749
Abstract

Lassa fever is an acute viral zoonotic illness caused by Lassa virus, a member of the Arenaviridae family and responsible for a severe hemorrhagic fever characterized by fewer, sour throat, muscle pain, nausea. In this work, we performed virtual screening against Nucleoprotein with entire 45 analogs compounds from Zinc Database using Auto Dock 4.2 software. These complexes were ranked according to their docking score, using methodology that was shown to achieve maximum accuracy. Finally we got six potent compounds with the best Auto dock docking Score. These six compounds were analyzed through Python Molecular Viewer for their interaction studies. From the docking result it was observed that ZINC79045769, ZINC04900951, ZINC21986245, ZINC75626110 have the lowest docking energy and thus have potential to inhibit the activity of nucleoprotein of Lassa virus. A 2-D pharmacophore was generated for these analogs using LigandScout to confirm it. A shared feature pharmacophore was also constructed that shows four common features (one hydrogen bond Donar, Two hydrogen bond Acceptor and one ionizable area) help compounds to interact with this enzyme.

Keywords

•    AutoDock 4.2
•    Ligand Scout
•    Nucleoprotein

Citation

Verma SK, Yadav S, Singh A, Kumar A (2015) Identification of Potential Inhibitor for Nucleoprotein of Lassa Virus: A Combination of Virtual Screening, ADMET Studies and Pharmacophore Modeling. J Drug Des Res 2(1): 1008.

INTRODUCTION

Lassa fever is an acute viral zoonotic illness caused by Lassa virus, a member of the Arenaviridae family and responsible for a severe hemorrhagic fever characterized by fever, sour throat, muscle pain, nausea [1]. Lassa fever was first described in Sierra Leone in the 1950s but the virus responsible for the disease was not identified until 1969 when two missionary nurses died in Nigeria, West Africa, and the cause of their illness was found to be Lassa virus, named after the town in Nigeria (Lassa in the Yedseram River valley) where the first cases were isolated [2,3]. There are an estimated 300,000 to 500,000 cases of Lassa fever each year [4,5] with a mortality rate if 15-20% for hospitalized patient. Mortality rate become high as 50% during epidemic and 90% in third month pregnancy for the expectant mother and the featus both [6-8]. Since then, a number of outbreaks of Lassa virus infection were reported in various parts of Nigeria including Jos, Zonkwua, Onitsha, Owerri, Abo Mbaise, Lafiya and Epkoma [9- 12]. Epidemics of Lassa fever were also documented in other West African countries including Liberia, Sierra Leone, Guinea, Mali and Senegal [2,10,13]. A few cases of the importation of Lassa virus into other parts of the world for example by travelers were documented.

Morphologically, Lassa virus consists of enveloped particles that vary in diameter from approximately 60 to more than 300 nm, with mean particle size of 92 nm. The virus is approximately spherical, enveloped particles that rang in diameter from 50 to 300 nm [14,15]. Lassa virus having ambisense genomic organization (two viral gene separated by an intergenic region), negative sense, bisegmented, ssRNA genome S (small ∼3.4 kb) & L (large ~7.2 kb) segments [16,17]. The small segment encodes the 75 KDa glycoprotein precursors (GPC) and the 63KDa nucleoprotein (NP). After part translation modification GPC cleaved in to GP1 and GP2. The large segment of RNA encodes the 11KDa Z protein, which binds zinc and as Matrix protein and the 200KDa L protein, which is act as matrix protein. Replication and transcription of the genome occurs in the cytoplasmic of an infected cell and both take place within Rib nucleoprotein complex [18,19].

Lassa virus is transmitted to human being from the rodent reservoir Mastomys natalensis, by direct content with infected tissue, food contaminated with excreta. Mostomys natalensis, is a common rodent in village houses, there for primary human infection are common. Lassa fever may also spread through person to person contact. Lassa virus transition occurs when a health person comes in to contact with virus in the blood, secretion, tissue or excretion of any infected individual. The virus cannot be transmitting through skin to skin contact without exchange of body fluid. Lassa virus enters the cell via the alphadystroglucan receptor [20]. Furthermore, ribavirin should be made available in hospitals and health centres in the endemic areas particularly in rural communities. This would help to control the disease.

The aim of this study to design the drug for Lassa virus. Structure based drug designing is an in silico technique which is very helpful in biological target identification, modeling of target protein virtual screening of potent drug compound and molecular docking studies to find out the best lead like compound. In the drug designing portion, we select the three inhibitors (Nucleozin, Naproxen and Ribavirin) and their analogs to predict the potential Nucleoprotein Inhibitors for Lassa virus using virtual screening, ADMET is screening and pharmacophore modeling. Nucleoprotein (NP) is a main drug targeted protein has distinct N- and C- terminal domains connected by a flexible linker. The Lassa virus nucleoprotein (NP) is a multifunctional protein that plays an essential role in many aspects of the viral life cycle, including RNA encapsidation, viral replication and transcription, recruitment of ribonucleoprotein complexes to viral budding sites, and inhibition of the host cell interferon response [21,22]. Nucleozin and Naproxen both are the nucleoprotein inhibitor while Ribavirin is used for the treatment of the infection of Lassa virus on clinical level.

MATERIAL AND METHODS

Structure retrieval and processing

For the docking analysis crystal structure of nucleoprotein was downloaded from database protein data bank (www.resb. org/pdb) with PDBID 3MWP A. The model contains solvent molecules along with hetero groups like its inhibitors and few of the calcium ions. Solvent and hetero groups were also removed using SPDBV Select and Build utilities. The crystal structure of nucleoprotein was further optimizing by energy minimization by Gromos96, implemented in Swiss PDB viewer software. This tool is form the molecular dynamic of the entire bonded and non banded atom with the model structure [23,24].

Active site Analysis

The active sites were revealed by Q site finder. It is a energy based method for the prediction of protein ligand binding site it uses the interaction energy between the protein and simple vander walls probe to locate energetically favorable binding site [25]. Energetically favorable probe sit were clustered according to their spatial proximity and cluster war ranked according to the sum of interaction energy.

Ligand Selection

The CID files of the ligands were downloaded from PubChem database. These files converted into PDB format by using Open Bable software [26]. Their energy minimization was carried out with the GROMOS96, implemented in Swiss-PDB viewer software [24]. GROMOS96 performs the molecular dynamics of all the bonded and non-bonded atoms with the model structure and obtain the minimum potential energy.

Zinc database screening

Zinc database contains over 13 million commercially available compounds in ready to dock and 3D format for structure based virtual screening. Zinc database is updated regularly and may be downloaded and used free of cost [27]. A total of 49 (17 Nucleozin + 16 Naproxen + 16 Ribavirin analogs) compounds were screened by using structure based searching method. These compounds were converted into PDB format from SDF by using Open Bable [26]. Their energy minimization was carried out with the GROMOS96, implemented in Swiss-PDB viewer software.

Virtual screening

Virtual screening is a key tool in structural molecular biology and computer added drug designing. In this docking studies are performed to product the predominant binding models of legend with a protein of know 3D structured. Molecular docking between selected compound and nucleoprotein crystal structure was done using Autodock 4.2 [28]. This program used a simulated annealing approach for explore the conformation space between the ligand and target protein. The energy evaluation process is done by using grid-based molecular affinity potential, the docking was performed on the basis of Lamarckian Genetic Algorithm. The energy grid was built within a box of dimension 68, 88, 78 for nucleoprotein with a spacing of 0.375 Å.

ADMET analysis

The compounds with good pharmacological and druggist property are very important to structure based drug designing. Pharmacological studies of lead molecule include absorption, distribution, metabolism, excretion and toxicity (ADMET) properties. These ADMET properties of the lead compounds were predicted by computational tools. Here, all 15 compounds identified were tested for their drug-likeliness, ADME profile and toxicity analysis by Pre-ADMET web tool. The ADMET includes the extent and rate of absorption, distribution, metabolism, excretion and toxicity. Absorption check the process of a substance entering the blood circulation, distribution explains the dispersion or dissemination of substances throughout the fluids and tissues of the body, metabolism or biotransformation is the irreversible transformation of parent compounds into daughter metabolites and excretion explains the process of removal of the substances from the body. Pre-ADMET use to predict drug likeness of compounds and check heterogeneous human epithelial colorectal adenocarcinoma cell lines (Caco2-cell) and Madin-Darby Canine Kidney (MDCK) cell models for oral drug absorption and skin permeability prediction, and human intestinal absorption model for drug absorption prediction. Similarly, the programme uses plasma protein binding models and blood brain barrier penetration (BBB) to predict the distribution. Pre-ADMET can predict the toxicity based on the mutagenicity of Ames test parameters and rodent carcinogenicity assays of mouse and rat [29].

Pharmacophore generation

Pharmacophore modeling is one of the most powerful computational method to categorize & identify key features from a large group of molecules and a 3D-pharmacophore is a set of interactions (functionalities or chemical features) aligned in three-dimensional space. Subsequently, pharmacophore model representing ligand-receptor binding derived from each of these small molecules and its neighboring amino acids. The pharmacophore models will provide a new insight to design new compounds that can inhibit the function of the target and will be useful in drug designing strategies [30]. Six compounds were taken on the basis of higher binding energy and best ADMET studies for pharmacophore modeling. Ligand scout (http://www.inteligand. com/ligandscout/) was used to develop pharmacophore model of selected compound. Different types of chemical feature and volume constraints for each selected compound were examined using feature directory from LigandScout software. By consolidating all the available features, six common features were used to generate pharmacophore model: Hydrogen bond donar, Hydrogen bond accepter, hydrophobic centroids, aromatic rings, cations, and anions.

RESULTS AND DISCUSSION

Active site analysis

Q-site finder detected the fallowing putative functional site residue for the targeted nucleoprotein protein MET54, ARG59, ASN71, VAL74, ASN75, LYS110, VAL113, ILE114, THR116, GLU117, ARG118, LEU120, SER121, ILE144, TRP164, ALA169, GLU170, LEU172, ASN173, ASN174, GLN175, PHE176, GLY177, THR178, MET179, LEU182. In this nucleoprotein protein the binding site cavity volume was 1166 cubic angstroms and it also showed that the coordinates the binding site box around predicted site had minimum cords 48, -63, -32 and maximum cords 73, -29, -7.

Virtual screening result

Docking studies was carried out using Autodock software to predict the interaction behavior of ligand with protein and residue involve in this interaction. The entire 52 compound were docked with the 3D crystal structure of Nucleoprotein. The docking results are shown in the Table 1 for Nucleozin and their analogs and Table 2 for Naproxen and their analogs and Table 3 for Ribavirin and their analogs. After the docking analysis of nucleoprotein with the selected compounds, sixteen compounds are screened out for the further analysis. After the ADME result of all sixteen compounds we select six compounds Nucleozin (-10.67), ZINC79045769 (-11.7), ZINC04900951 (-11.57), Naproxen (-11.73), ZINC21986245 (-12.32) and ZINC75626110 (-11.91) as potent inhibitor.

ADMET analysis

ADMET profiles determine drug like activity of the ligand molecules based on Lipinski rule of 5, rate of absorption, distribution, metabolism, and excretion and toxicity based on Ames test and rodent carcinogenicity assay. Increasing clinical failures of new drugs call for a more effective use of ADMET technologies. Drug-likeliness and ADME profile prediction of selected compounds using by Pre-ADMET tool shown in Table 4 and Table 5 respectively. The main rules used to test the drug likeliness were Lipinski’s Rule, Lead like Rule, CMC-like rule, MDDR-like rule and WDI-like rule and ADME profile (caco-2, MDCK, BBB, HIA, plasma protein binding and skin permeability data) analysis. Some compounds are Non-qualified and failure in some rules. Toxicity prediction is the final step of ADMET analysis of selected lead compounds. In this toxicity prediction study, we have found that the predicted toxicities of selected compounds were suitable for further studies (Table 6). ZINC79045769 and ZINC04900951 analogs of Nucleozin and ZINC21986245 and ZINC75626110 analogs of Naproxen showed better drug likeness, pharmacokinetics and toxicity properties. Hence, these lead compounds were identified as the best ligands for pharmacophore modeling.

Pharmacophore generation

After virtual screening and ADMET studies we select four best compounds for the pharmacophore generation. Pharmacophore model generation was done for all six compounds by using Ligand scout which are shown in (Figures 1-4) Shared featured pharmacophore of Nucleozin with analogs and Naproxen with analogs were generated by aligning pharmacophores and molecules using reference points as shown in (Figure 5).

Predicted pocket (red color) of Nucleoprotein and involved amino acid.

Figure 1: Predicted pocket (red color) of Nucleoprotein and involved amino acid.

Docking conformation of: a) Nucleozin b) ZINC79045769 c) ZINC04900951 analyzed by Python Molecular Viewer (docked ligand shown by balls and sticks while hydrogen bonds shown by black sticks.

Figure 2: Docking conformation of: a) Nucleozin b) ZINC79045769 c) ZINC04900951 analyzed by Python Molecular Viewer (docked ligand shown by balls and sticks while hydrogen bonds shown by black sticks.

Docking conformation of: a) Naproxen b) ZINC21986245 c) ZINC75626110 analyzed by Python Molecular Viewer (docked ligand shown by balls and sticks while hydrogen bonds shown by black sticks.

Figure 3: Docking conformation of: a) Naproxen b) ZINC21986245 c) ZINC75626110 analyzed by Python Molecular Viewer (docked ligand shown by balls and sticks while hydrogen bonds shown by black sticks.

3-D Pharmacophore model of a) Nucleozin b) ZINC79045769 c) ZINC04900951 d) overlapped model of ZINC79045769 and ZINC04900951 generated by LigandScout (hydrogen bond Donor: green sphere, hydrogen bonds Acceptor: Red sphere and ionizable area: Blue asterisk and Aromatic rings).

Figure 4: 3-D Pharmacophore model of a) Nucleozin b) ZINC79045769 c) ZINC04900951 d) overlapped model of ZINC79045769 and ZINC04900951 generated by LigandScout (hydrogen bond Donor: green sphere, hydrogen bonds Acceptor: Red sphere and ionizable area: Blue asterisk and Aromatic rings).

3-D Pharmacophore model of a) Naproxen b) ZINC21986245 c) ZINC75626110 d) overlapped model of ZINC21986245 and ZINC75626110 generated by Ligand Scout (hydrogen bond Donor: green sphere, hydrogen bonds Acceptor: Red sphere and ionizable area: Blue asterisk and Aromatic rings).

Figure 5: 3-D Pharmacophore model of a) Naproxen b) ZINC21986245 c) ZINC75626110 d) overlapped model of ZINC21986245 and ZINC75626110 generated by Ligand Scout (hydrogen bond Donor: green sphere, hydrogen bonds Acceptor: Red sphere and ionizable area: Blue asterisk and Aromatic rings).

Table 1: Docking results of Nucleozin analogs with Nucleoprotein.

ZINC_ID xLogP Polar Desolvation H Donors H Acceptors Molecular Weight Rotatable Bonds Docking Energy Build H Bond
Nucleozin 3.9 -11.34 0 6 426.852 3 -10.67 3
ZINC08781115 3.37 -11.83 0 8 426.86 4 -9.94 2
ZINC22064357 3.70 -11.9 0 8 440.887 4 -8.90 1
ZINC22064361 3.70 -12.68 0 8 461.305 4 -7.94 2
ZINC08855058 4.00 -12.26 0 8 400.822 4 -12.02 3
ZINC04974049 3.48 -16.33 2 8 426.86 7 -8.09 2
ZINC16677244 3.34 -13.31 0 8 475.332 4 -9.66 1
ZINC20076590 4.33 -12.51 0 8 475.332 4 -9.05 1
ZINC20076587 4.33 -14.11 0 8 396.878 4 -9.76 0
ZINC79045769 2.48 -11.15 2 6 435.267 3 -11.72 3
ZINC22064878 4.12 -17.52 2 8 381.863 7 -9.32 2
ZINC06912077 3.43 -10.69 0 5 426.86 3 -10.75 2
ZINC08454078 3.37 -12.45 0 8 461.305 4 -8.59 2
ZINC22064955 3.97 -13.62 0 8 392.415 4 -10.05 1
ZINC04900951 2.76 -17.99 0 8 461.305 4 -11.57 3
ZINC08435355 4.02 -14.59 0 8 461.305 4 -10 2
ZINC08435353 3.39 -14.44 0 8 426.86 4 -8.56 1
ZINC04565291 3.46 -15.53 2 8 400.822 7 -9.73 0

Table 2: Docking results of Naproxen analogs with Nucleoprotein.

ZINC_ID xLogP Polar Desolvation H Donors H Acceptors Molecular Weight Rotatable Bonds Docking Energy Build H Bond
Naproxen 3.3 -47.28 1 3 230.259 3 -11.73 2
ZINC00105216 3.38 -47.82 0 3 229.255 3 -8.43 1
ZINC00113439 3.38 -48.58 0 3 229.255 3 -7.22 1
ZINC01843439 3.55 -50.37 0 3 243.282 3 -10.56 1
ZINC71610607 3.55 -49.05 0 3 229.255 3 -11.01 0
ZINC06030355 3.55 -49.67 0 3 229.255 3 -9.67 1
ZINC02014886 2.58 -49.03 0 3 215.228 3 -8.98 1
ZINC06030370 2.88 -47.85 0 3 229.255 3 -9.32 0
ZINC06037142 2.88 -49.51 0 3 229.255 3 -9.45 1
ZINC06037131 2.84 -49.29 1 3 215.228 2 -12.03 2
ZINC02570852 2.84 -47.00 3 3 215.228 2 -11.53 2
ZINC75626106 2.84 -47.32 1 3 215.228 2 -9.31 1
ZINC75626110 2.84 -48.93 1 3 215.228 2 -11.91 2
ZINC77303118 3.28 -49.01 0 3 243.282 3 -8.33 0
ZINC77303121 3.28 -49.23 0 3 243.282 3 -7.43 1
ZINC21986247 3.35 -9.15 3 0 244.29 4 -8.37 1
ZINC21986245 3.35 -9.15 3 0 244.29 4 -12.32 2

Table 3: Docking results of Ribavirin analogs with Nucleoprotein.

ZINC_ID xLogP Polar Desolvation H Donors H Acceptors Molecular Weight Rotatable Bonds Docking Energy Build H Bond
Ribavirin -1.8 -18.73 4 7 244.204 3 -10.67 3
ZINC00896749 -2.77 -16.15 5 9 244.207 3 -10.91 3
ZINC21981355 -2.77 -21.78 5 9 244.207 3 -8.87 2
ZINC06603353 -2.77 -21.52 5 9 244.207 3 -9.55 2
ZINC21981353 -2.77 -24.81 5 9 244.207 3 -11.98 4
ZINC01035331 -2.77 -17.41 5 9 244.207 3 -9.12 2
ZINC01091444 -2.77 -18.93 5 9 244.207 3 -8.82 2
ZINC03831418 -2.77 -16.84 5 9 244.207 3 -10.45 3
ZINC03831419 -2.77 -17.96 5 9 244.207 3 -9.34 3
ZINC03831420 -2.77 -15.05 5 9 244.207 3 -12.34 5
ZINC03831421 -2.77 -21.51 5 9 244.207 3 -12.87 4
ZINC04245717 -2.77 -19.79 5 9 244.207 3 -9.98 4
ZINC28463692 -2.77 120.4 5 9 244.207 3 -8.76 1
ZINC05291792 -2.07 -27.38 4 10 286.244 5 -7.23 3
ZINC05291810 -2.07 -22.06 4 10 286.244 5 -8.93 2
ZINC05291808 -2.07 -24.15 4 10 286.244 5 -10.65 2
ZINC05291797 -2.07 -21.81 4 10 286.244 5 -12.90 3

Table 4: Drug-likeliness prediction of selected compounds using Pre-ADMET tool. The main rules used to test the drug likeliness were Lipinski’s Rule, Lead like Rule, CMC-like rule, MDDR-like rule and WDI-like rule.

Compound Lipinski's Rule Lead like Rule CMC-like rule MDDR-like rule WDI-like rule
Nucleozin Suitable Violated Qualified Mid-structure In 90% cutoff
ZINC08855058 Suitable Violated Qualified Mid-structure In 90% cutoff
ZINC79045769 Suitable Violated Qualified Mid-structure In 90% cutoff
ZINC04900951 Suitable Violated Qualified Mid-structure In 90% cutoff
ZINC06912077 Suitable Violated Qualified Mid-structure In 90% cutoff
Naproxen Suitable Suitable Qualified Mid-structure In 90% cutoff
ZINC21986245 Suitable Violated Qualified Mid-structure In 90% cutoff
ZINC06037131 Suitable Suitable Failed Mid-structure In 90% cutoff
ZINC75626110 Suitable Suitable Non-qualified Mid-structure Failed
ZINC02570852 Suitable Suitable Failed Mid-structure Failed
Ribavirin Suitable Violated Qualified Mid-structure In 90% cutoff
ZINC05291797 Suitable Violated Qualified Mid-structure Failed
ZINC03831420 Suitable Violated Non-qualified Mid-structure In 90% cutoff
ZINC03831421 Suitable Violated Non-qualified Mid-structure In 90% cutoff
ZINC21981353 Suitable Violated Non-qualified Mid-structure In 90% cutoff

Table 5: ADME prediction of compounds using Pre-ADMET tool.

Compound Human
Intestinal
Absorption
Caco2 Cell
Permeability
MDCK Cell
Permeability
Plasma protein 
biding
Blood Brain
Barrier
Penetration
Nucleozin 99.522063 20.1692 0.0755843 98.999182 0.298094
ZINC08855058 99.136228 17.9378 0.0564337 98.480451 0.294334
ZINC79045769 96.663744 22.9271 0.198448 88.368975 0.0462123
ZINC04900951 98.832066 7.79045 0.586648 91.185904 0.212613
ZINC06912077 97.485649 41.3096 0.151602 91.387010 0.10315
Naproxen 98.089935 14.7189 185.873 93.954170 0.042197
ZINC21986245 98.697048 29.7656 105.055 90.868524 0.0915844
ZINC06037131 95.674448 4.84276 109.044 86.393242 0.903749
ZINC75626110 95.674448 21.122 109.044 87.118936 0.903749
ZINC02570852 95.674448 4.84276 109.044 86.393242 0.903749
Ribavirin 21.502254 1.36443 2.22093 7.329473 0.150118
ZINC05291797 23.068541 3.34818 0.900147 8.068397 0.011005
ZINC03831420 21.502254 1.36443 2.22093 7.329473 0.150118
ZINC03831421 21.502254 1.36443 2.22093 7.329473 0.150118
ZINC21981353 21.502254 1.36443 2.22595 7.329473 0.150118

Table 6: Toxicity prediction of selected compounds by Pre-ADMET tool.

Compound AMES Test Carcinogenicity
TA100 TA100 TA1535 TA1535 TA98 TA98 Result Mouse Rat
+s9 -s9 +s9 -s9 +s9 -s9
Nucleozin + - + - - + M - -
ZINC08855058 + - + - - - M - +
ZINC79045769 + + + - + - M - -
ZINC04900951 + + - - - + M - -
ZINC06912077 + - + - - - M - +
Naproxen + - - - + + M - -
ZINC21986245 - - - - + + M - -
ZINC06037131 + - - - + + M - +
ZINC75626110 + - - - + + M - -
ZINC02570852 + - - - + + M - +
Ribavirin - - + - + - M - +
ZINC05291797 - - + - + - M - +
ZINC03831420 - - + - + - M - +
ZINC03831421 - - + - + - M - +
ZINC21981353 - - + - + - M - +
CONCLUSION

The Nucleoprotein of Lassa Virus is the drug targeting proteins for the drug discovery fighting with the current pandemic. Crystal structure of nucleoprotein was downloaded from database protein data bank (www.resb.org/pdb) with PDBID 3MWP A. All Fifty two compounds screened from ZINC database were docked with crystal structure of Nucleoprotein. After docking four compounds ZINC79045769, ZINC04900951, ZINC21986245, ZINC75626110 were predicted as potent candidate drugs for Lassa Virus. Yet pharmacological studies have to confirm it.

REFERENCES

1. Centers for Disease Control and Prevention (CDC). Imported Lassa fever--New Jersey, 2004. MMWR Morb Mortal Wkly Rep. 2004; 53: 894-897.

2. Frame JD, Baldwin JM Jr, Gocke DJ, Troup JM. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg. 1970; 19: 670-676.

3. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986; 314: 20-26.

4. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis. 1987; 155: 437-444.

5. McCormick JB, King IJ, Webb PA, Johnson KM, O’Sullivan R, Smith ES, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis. 1987; 155: 445-455.

6. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis. 1987; 155: 456-464.

7. McCormick JB. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med Microbiol Immunol. 1986;175:153-155.

8. McCormick JB. Epidemiology and control of Lassa fever. Curr Top Microbiol Immunol. 1987; 134: 69-78.

9. Carey DE, Kemp GE, White HA, Pinneo L, Addy RF, Fom AL, et al. Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria. Trans R Soc Trop Med Hyg. 1972; 66: 402-408.

10. Bowen GS, Tomori O, Wulff H, Casals J, Noonan A, Downs WG,. Lassa fever in Onitsha, East Central State, Nigeria in 1974. Bull World Health Organ. 1975; 52: 599-604.

11. Monath TP. Lassa fever: review of epidemiology and epizootiology. Bull World Health Organ. 1975; 52: 577-592.

12. Tim Menakayi. Public health leaflets on what your need to know about Lassa fever. Abuja, Nigeria: Federal Ministry of Health. 2000.

13. Monath TP, Maher M, Casals J, Kissling RE, Cacciapuoti A. Lassa fever in the Eastern Province of Sierra Leone, 1970–1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg 1974; 23: 1140–1149.

14. Auperin DD, Sasso DR, McCormick JB. Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology. 1986; 154: 155-167.

15. Auperin DD, McCormick JB. Nucleotide sequence of the Lassa virus (Josiah strain) S genome RNA and amino acid sequence comparison of the N and GPC proteins to other arenaviruses. Virology. 1989; 168: 421-425.

16. Schmitz H, Köhler B, Laue T, Drosten C, Veldkamp PJ, Günther S, et al. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect. 2002; 4: 43-50.

17. Buchmeier MJ, De la Torre JC, Peters CJ. Arenaviridae: The viruses and their replication. In: Fields virology, 5th ed. Philadelphia. Knipe DM, Howley PM, editors. Lippincott Williams & Wilkins. 2007; 1791-1827.

18. Günther S, Emmerich P, Laue T, Kühle O, Asper M, Jung A, et al. Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis. 2000; 6: 466-476.

19. Lozano ME, Posik DM, Albarino CG, Schujman G, Ghiringhelli PD, Calderon G, et al. Characterisation of arenaviruses using a familyspecific primer set for RT-PCR amplification and RFLP analysis. Its potential use for detection of uncharacterised arenaviruses. Virus Res. 1997; 49: 79–89.

20. Keenlyside RA, McCormick JB, Webb PA, Smith E, Elliott L, Johnson KM. Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. Am J Trop Med Hyg. 1983; 32: 829-837.

21. Lennartz F, Hoenen T, Lehmann M, Groseth A, Garten W. The role of oligomerization for the biological functions of the arenavirus nucleoprotein. Arch Virol. 2013; 158: 1895-1905.

22. Hastie KM, Liu T, Li S, King LB, Ngo N, Zandonatti MA, et al. Crystal structure of the Lassa virus nucleoprotein–RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci U S A. 2011; 108: 19365–19370.

23. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, Gasteiger E, et al. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res. 2003; 31: 365-370.

24. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling. Electrophoresis. 1997; 18: 2714-2723.

25. Laurie AT, Jackson RM. Q-Site Finder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics. 2005; 21: 1908-1916.

26. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011; 3: 33.

27. Irwin JJ, Shoichet BK. ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005; 45: 177- 182.

28. Goodsell DS, Morris GM, Halliday RS, Huey R, Belew RK, Olson AJ. Automated Docking using a Lamarckian Genetic Algorithm and Empirical Binding free energy function. J. Computational Chemistry, 1998: 19: 1639-1662.

29. Seal A, Aykkal R, Babu RO, Ghosh M. Docking study of HIV-1 reverse transcriptase with phytochemicals. Bioinformation. 2011; 5: 430-439.

30. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005; 45: 160-169.

Verma SK, Yadav S, Singh A, Kumar A (2015) Identification of Potential Inhibitor for Nucleoprotein of Lassa Virus: A Combination of Virtual Screening, ADMET Studies and Pharmacophore Modeling. J Drug Des Res 2(1): 1008.

Received : 14 Feb 2015
Accepted : 10 Mar 2015
Published : 13 Mar 2015
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X